StockDriftsStockDriftsTop 3 Mwg Management Ltd. Holdings
| Stock | Company | % Port. | Shares | Value | Activity | Ownership | Avg. Cost | Date |
|---|---|---|---|---|---|---|---|---|
| BEAM | BEAM THERAPEUTICS INC | 67.66% | 2.27M | $55.0M | +0.00%(+0) | $93.60(-70.11%) | 2025-09-30 | |
| LYEL | LYELL IMMUNOPHARMA INC | 20.13% | 1.01M | $16.4M | new | $332.05(-89.43%) | 2025-09-30 | |
| PRME | PRIME MEDICINE INC | 12.21% | 1.79M | $9.9M | +0.00%(+0) | $17.57(-80.08%) | 2025-09-30 |
| Performance Metric | 3-Year Annualized | 3-Year Cumulative | 5-Year Annualized | 5-Year Cumulative | Since First Filing (12 quarters) |
|---|---|---|---|---|---|
| Top 20 Holdings Weighted | -35.96% | -73.74% | — | — | -73.74% |
| Top 20 Holdings Unweighted | -35.87% | -73.63% | — | — | -73.63% |
Mwg Management Ltd. reports $81.32M in US-listed equity holdings across 3 positions in its most recent 13F filing. Its largest disclosed positions are BEAM (67.7%), LYEL (20.1%) and PRME (12.2%). The top 20 holdings account for 100% of reported assets. Its disclosed equity book has returned -73.74% on a three-year cumulative basis. Figures reflect the Q3 2025 filing.
Portfolio changes
Every reported change this quarter, grouped by direction. The signal is in the rotation, not any single trade.
Sign up free to track Mwg Management Ltd., compare funds side by side, and get alerts the moment positions change.
Holdings on this page are parsed from Mwg Management Ltd.’s Form 13F filings with the U.S. Securities and Exchange Commission (CIK 1845151). View Mwg Management Ltd.’s 13F filings on SEC